Summary: continuous VEGF inhibition – a promising treatment strategy
VEGF is one of the most potent and predominant, known pro-angiogenic factors and is both present and stable throughout the tumour life cycle. Preclinical evidence supports maintaining direct and continuous VEGF suppression over time. As tumours develop, continued VEGF suppression is thought to provide important ongoing antivascular effects that may inhibit further growth and spread of tumour cells. Therefore, one area of anti-angiogenesis research that is being pursued is the strategy of maintaining precise VEGF inhibition as tumours progress and supplementing it with selective targeting of other emergent pathways.
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.